Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Journal of Drug Assessment|May 10, 2019
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologistsPedro Sánchez-Rovira, Pilar Zamora, Javier Salvador-Bofill, et al.
NPJ Breast Cancer|February 10, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 5, 2024
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) studyÁlvaro Rodríguez-Lescure, Javier Gallego, Pilar Garcia-Alfonso, et al.
The Lancet. Oncology|May 1, 2018
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trialSonia Pernas, Miguel Martin, Peter A Kaufman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerNancy U Lin, Véronique Diéras, Devchand Paul, et al.
Nature Communications|January 22, 2020
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockadeFara Brasó-Maristany, Gaia Griguolo, Tomás Pascual, et al.
Scientific Reports|September 1, 2017
Functional proteomics outlines the complexity of breast cancer molecular subtypesAngelo Gámez-Pozo, Lucía Trilla-Fuertes, Julia Berges-Soria, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Pageof 13